Search results
Showing 251 to 300 of 314 results for breast cancer
Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer [ID6433]
Awaiting development Reference number: GID-TA11489 Expected publication date: TBC
Awaiting development Reference number: GID-TA11110 Expected publication date: TBC
In development Reference number: GID-TA11588 Expected publication date: TBC
In development Reference number: GID-TA11342 Expected publication date: TBC
In development Reference number: GID-TA10960 Expected publication date: TBC
In development Reference number: GID-TA11546 Expected publication date: TBC
In development Reference number: GID-TA11771 Expected publication date: TBC
Discontinued Reference number: GID-TAG410
Advanced breast cancer: diagnosis and management (Partial update)
In development Reference number: GID-NG10430 Expected publication date: TBC
Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]
Awaiting development Reference number: GID-TA11565 Expected publication date: 21 May 2026
In development Reference number: GID-TA11862 Expected publication date: TBC
In development Reference number: GID-TA11439 Expected publication date: TBC
All NICE products on breast cancer. Includes any guidance, advice and quality standards.
Veliparib in combination for treating BRCA-positive, HER2-negative breast advanced cancer [ID1404]
Discontinued Reference number: GID-TA10327
Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy [ID1260]
Discontinued Reference number: GID-TA10309
Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]
Discontinued Reference number: GID-TA10295
In development Reference number: GID-TA11519 Expected publication date: 12 June 2026
Familial Breast Cancer: initial assessment and genetic testing (update)
In development Reference number: GID-NG10438 Expected publication date: 22 April 2027
Awaiting development Reference number: GID-TA11835 Expected publication date: TBC
Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]
Discontinued Reference number: GID-TA11411
In development Reference number: GID-TA11774 Expected publication date: 30 September 2026
In development Reference number: GID-TA11674 Expected publication date: 07 May 2026
Awaiting development Reference number: GID-TA11686 Expected publication date: TBC
In development Reference number: GID-TA11687 Expected publication date: TBC
Awaiting development Reference number: GID-TA11487 Expected publication date: TBC
Image-guided high intensity focused ultrasound to treat breast cancer
Topic prioritisation
NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.
Breast reconstruction using lipomodelling after breast cancer treatment (IPG417)
Interventional procedures, IPG417 - Issued: January 2012 --> We have moved interventional procedures guidance 417 to become HealthTech guidance 280. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Endoscopic mastectomy and endoscopic wide local excision for breast cancer (IPG296)
Interventional procedures, IPG296 - Issued: April 2009 --> We have moved interventional procedures guidance 296 to become HealthTech guidance 188. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Interventional procedures, IPG268 - Issued: July 2008 --> We have moved interventional procedures guidance 268 to become HealthTech guidance 171. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved interventional procedures guidance 89 to become HealthTech guidance 55. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer (MTG72)
We have moved Medical technologies guidance 72 to become HealthTech guidance 642. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG34)
This guidance has been updated and replaced by NICE diagnostics guidance 58.
Endoscopic axillary lymph node retrieval for breast cancer (IPG147)
We have moved interventional procedures guidance 147 to become HealthTech guidance 93. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG58)
We have moved Diagnostics guidance 58 to become HealthTech guidance 719. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved Diagnostics guidance 8 to become HealthTech guidance 315. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
This guidance has been updated and replaced by NICE guideline CG41.
This guidance has been updated and replaced by NICE guideline CG164.
Early and locally advanced breast cancer: diagnosis and treatment (CG80)
This guideline has been updated and replaced by NICE guideline NG101.
Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive early breast cancer [ID6620]
Awaiting development Reference number: GID-TA11403 Expected publication date: TBC
This guideline has been updated and replaced by NICE guideline NG101.
Bevacizumab for the first-line treatment of metastatic breast cancer (TA147)
This appraisal has been updated and replaced by NICE technology appraisal 214.
This guidance has been updated and replaced by NICE technology appraisal guidance 1040.
This guidance has been updated and replaced by NICE technology appraisal guidance 836.
This appraisal has been updated and replaced by NICE guideline CG81.
This guidance has been updated and replaced by NICE technology appraisal guidance 816.
Eribulin for the treatment of locally advanced or metastatic breast cancer (TA250)
This guidance has been updated and replaced by NICE technology appraisal guidance 423 and NICE technology appraisal guidance 515.